Highlights Astellas Pharma Inc.

Equities

4503

JP3942400007

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
1,558 ^JPY	+2.16%		+3.45%	-7.59%

May. 02	Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	MT
May. 01	Malin Corp investee signs agreement with Astellas Pharma	AN

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	May. 02	MT
Malin Corp investee signs agreement with Astellas Pharma	May. 01	AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	May. 01	DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30	RE
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024	Apr. 25	CI
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024	Apr. 25	CI
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	Apr. 25	CI
European Commission Approves Astellas Pharma Label Extension for Xtandi	Apr. 24	MT
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting	Apr. 23	CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	Apr. 22	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	Apr. 22	CI
Lupin Launches Mirabegron Extended-Release Tablets in US	Apr. 21	MT
Japan Inc makes a renewed U.S. push as China fears mount	Apr. 17	RE
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	Apr. 15	MT
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Apr. 12	CI
U.S. FDA Accepts Astellas? Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy	Mar. 31	CI
Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China	Mar. 28	MT
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	Mar. 28	CI
Final dividend	Mar. 27	FA
Astellas Pharma Inc.'s Vyloy?? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer	Mar. 26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Astellas Pharma Inc.

Equities

4503

JP3942400007

Highlights

Filters